Science Bridges China Research Profile

Name: **Professor Laurence Patterson**

Position: **Director, Institute of Cancer Therapeutics;**

Institute/division: **School of Life Sciences, University of Bradford**

Email: **l.h.patterson@bradford.ac.uk**

Tel: **(00) 44 1274 3225**

SUMMARY OF MY RELEVANT RESEARCH AREAS:

Anti cancer drug discovery
Delivery devices for anticancer drugs
Taste masking of TCM's and API's
Pharmacological taste masking (bitter taste Sensomics)
Fluorescent probe development for informing cell content and cell activity

抗肿瘤药物新药研究
抗肿瘤药物载体研究
药物掩味技术研究
掩味药理学研究
荧光法检测细胞活性

Primary Research interests:

- Tumour-selective drug activation
- The glycocalyx as a target for drug discovery
- Modulators of integrin activity
- Bioreductive activation of drugs in hypoxia tumours
- Cytochromes P450 in tumours

Topics in which you would like to develop collaborative research:

Cancer Therapeutics

Relevant existing collaborations (academic/clinical/commercial) inside or outside China.
Chinese collaborators 中国合作伙伴
Prof Bian, Dept Pathology, Southwest Hospital, TMMU Chongqing 卞教授，西南医院病理学研究所，第三军医大学，重庆
Prof Zhou, Inst Biopharmaceutics, TMMU, Chongqing 周教授，生物制药研究室，第三军医大学，重庆
Prof Cui, Department of Stem Cell Biology & Regenerative Medicine, Southwest University, Chongqing 崔教授，干细胞与再生医学研究所，西南大学，重庆
Prof Fang, IMM, Beijing 方教授，中国医学科学院北京协和医学院药物研究所，北京
Prof Feng, TCM University, Shanghai 冯教授，上海中医药大学，上海
Prof Zhang, SIMM, Shanghai 张教授，中国科学院上海药物研究所，上海

Outside China 中国以外合作伙伴
major Collaboration with St James's hospital University of Leeds (Experimental Cancer Medicine Centre partner)
利兹大学 St James's 医院（肿瘤医学实验中心）

major Collaboration with Prof Magnus Ingelman-Sundberg, Department of Physiology and Pharmacology KarolinskaInstitute, Sweden
Magnus Ingelman-Sundberg 教授，生理与药理研究所，卡罗林斯卡医学院，瑞典

Relevant graphics, figures, pictures:


Medicinal Chemistry



Proteomics & mass spectroscopy


Drug Metabolism and Pharmacokinetics

Publications and other outputs relevant to your interest in this programme

•Veiga, J.P., Cooper, P.A., Pors, K., Patterson, L.H., Bibby, M.C., Shnyder, S.D. "Use of the hollow fiber assay for the evaluation of DNA damaging agents," J Pharmacol Toxicol Methods (2011) Apr 30. [Epub ahead of print] PubMed PMID: 21569858.
•Vinader, V., Al-Saraireh, Y., Wiggins, H.L., Rappoport, J.Z., Shnyder, S.D., Patterson, L.H., Afarinkia, K. "An agarose spot chemotaxis assay for chemokine receptor antagonists," J Pharmacol Toxicol Methods (2011) Feb 1. [Epub ahead of print] PubMed PMID:21292017.
•Atkinson, J.M., Falconer, R.A., Edwards, D.R., Pennington, C.J., Siller, C.S., Shnyder, S.D., Bibby, M.C., Patterson, L.H., Loadman, P.M., Gill, J.H. "Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases" Cancer Res. (2010) Sep 1;70(17):6902-12. Epub 2010 Jul 27.PubMed PMID: 20663911; PubMed Central PMCID: PMC2933508.
•Sutton, C.W., Sutherland, M., Shnyder, S., Patterson, L.H. "Improved preparation and detection of cytochrome P450 isoforms using MS methods," Proteomics. (2010) Jan;10(2):327-31. PubMed PMID: 19902426.
•Sheldrake, H.M. and Patterson, L.H., "Function and antagonism of beta3 integrins in the development of cancer therapy," Curr Cancer Drug Targets, (2009), Jun; 9(4):519-40. PMID: 19519320
•Seibert, C., Davidson, B.R., Fuller, B.J., Patterson, L.H., Griffith, W.J., and Wang, Y., "Multiple-approaches to the identification and quantification of cytochromes P450 in human liver tissue by mass spectrometry," J Proteome Res. (2009) Apr; 8(4): 1672-81. PubMed PMID: 19714871